title: Chronic intrauterine pulmonary hypertension increases endothelial cell Rho kinase activity and impairs angiogenesis in vitro.
abstract: Persistent pulmonary hypertension of the newborn (PPHN) is characterized by endothelial dysfunction and decreased vascular growth. The role of Rho kinase activity in modulating endothelial function and regulating angiogenesis during normal lung development and in PPHN is unknown. We hypothesized that PPHN increases Rho kinase activity in fetal pulmonary artery endothelial cells (PAECs) and impairs angiogenesis in vitro. Proximal PAECs were harvested from fetal sheep with partial ligation of the ductus arteriosus in utero (PPHN) and age-matched controls. Rho kinase activity was measured by RhoA, Rho GTP, and phosphorylated MYPT-1 protein content. The effects of Rho kinase activity on angiogenesis, endothelial nitric oxide (NO) synthase (eNOS) protein expression, and NO production were determined in normal and PPHN PAECs. Angiogenesis was assessed by tube formation in vitro with/without Y-27632 (a Rho kinase inhibitor) and calpeptin (a Rho kinase activator) in the presence/absence of N-nitro-l-arginine (l-NA, an NOS inhibitor). RhoA, Rho GTP, and phosphorylated MYPT-1 protein were increased in PPHN PAECs. Tube formation was reduced 29% in PPHN PAECs (P < 0.001) and increased with Y-27632 treatment in normal and PPHN PAECs, with PPHN PAECs achieving levels similar to those of normal PAECs. l-NA inhibited the Y-27632-induced increase in tube formation in normal, but not PPHN, PAECs. Calpeptin reduced tube formation in normal and PPHN PAECs. eNOS expression was reduced 42% in PPHN PAECs (P < 0.01). Y-27632 increased eNOS protein and NO production in normal and PPHN PAECs. Calpeptin decreased eNOS protein only in normal PAECs but reduced NO production in normal and PPHN PAECs. We conclude that Rho kinase activity is increased in PPHN PAECs and impairs angiogenesis and downregulates eNOS protein and NO production in vitro.
authors.affiliation: Department of Pediatrics, University of Colorado School of Medicine, Denver, CO, USA. jason.gien@uchsc.edu
authors.forename: Jason
authors.initials: J
authors.lastname: Gien
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Seedorf
authors.forename: Vivek
authors.initials: V
authors.lastname: Balasubramaniam
authors.forename: Nancy
authors.initials: N
authors.lastname: Tseng
authors.forename: Neil
authors.initials: N
authors.lastname: Markham
authors.forename: Steven H
authors.initials: SH
authors.lastname: Abman
mesh_terms: D000818:Animals; D002462:Cell Membrane / Q000201:enzymology / Q000502:physiology; D002908:Chronic Disease; D004151:Dipeptides / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000201:enzymology / Q000503:physiopathology*; D005260:Female; D006976:Hypertension, Pulmonary / Q000196:embryology* / Q000503:physiopathology*; D043263:Myosin-Light-Chain Phosphatase / Q000378:metabolism; D018919:Neovascularization, Physiologic / Q000502:physiology*; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010766:Phosphorylation; D011247:Pregnancy; D012756:Sheep; D054460:rho-Associated Kinases / Q000187:drug effects / Q000378:metabolism*
chemical_list: D004151:Dipeptides; C071482:calpeptin; D052250:Nitric Oxide Synthase Type III; D054460:rho-Associated Kinases; D043263:Myosin-Light-Chain Phosphatase